These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10050100)

  • 1. How to save money for erythropoietin therapy by changing from 'roller coaster' to continuous iron supplementation.
    Canavese C; Grill A; De Costanzi E; Martina G; Buglione E; Valente D; David O; Saitta M; Maddalena E; Barbieri S; Fop F; Salomone M; Piccoli G
    Nephron; 1999; 81(3):362-3. PubMed ID: 10050100
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy.
    Kao HH; Chen KS; Tsai CJ; Lee CC; Chang HY
    Chang Gung Med J; 2000 Oct; 23(10):608-13. PubMed ID: 11126152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance and use of iron supplementation in uremia.
    Makoff R
    Nephrol News Issues; 1992 Jun; 6(6):14-6, 19. PubMed ID: 1608475
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Sadjadi SA
    Am J Kidney Dis; 1995 Dec; 26(6):1000-1. PubMed ID: 7503060
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Perazella MA
    Am J Kidney Dis; 1995 Dec; 26(6):1000; author reply 1001. PubMed ID: 7503059
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of intravenous iron in chronic renal patients with anemia. Higher levels of hemoglobin at a lower cost].
    Cuero CJ; Pérez E; de Rivera C
    Rev Med Panama; 1998; 23(1):14-6. PubMed ID: 10997188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis.
    Kato A; Hamada M; Suzuki T; Maruyama T; Maruyama Y; Hishida A
    Nephron; 2001 Sep; 89(1):110-2. PubMed ID: 11528242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron therapy: overview and recommendations.
    Macdougall IC
    Przegl Lek; 1998; 55 Suppl 1():72. PubMed ID: 9857704
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
    Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
    Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin.
    Weiss G; Meusburger E; Radacher G; Garimorth K; Neyer U; Mayer G
    Kidney Int; 2003 Aug; 64(2):572-8. PubMed ID: 12846752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later.
    Weiner DE; Winkelmayer WC
    Am J Kidney Dis; 2013 Dec; 62(6):1217-20. PubMed ID: 24267389
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.
    Rao DS; Shih MS; Mohini R
    N Engl J Med; 1993 Jan; 328(3):171-5. PubMed ID: 8417383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is hematologic response to iron and erythropoietin in hemodialysis patients affected by other factors?
    Acchiardo SR; Moore LW; Sargent JA; Burk LB
    ASAIO Trans; 1991; 37(3):M183-5. PubMed ID: 1751102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.